C-ITGTAeovian Pharmaceuticals
selective mTORC1 inhibition, CD38 inhibition, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ITGT
C-ITGTC-ITGTselective mTORC1 inhibition, CD38 inhibition, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This Phase 1 study in healthy adult volunteers is planned to evaluate the safety, tolerability, and pharmacokinetics (PK) of AV078, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1). The study will begin with a standard exploration of safety and tolerability in sequential single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Subsequent cohorts will collect PK data to evaluate food effects and potential drug-drug interactions relevant to AV078.
Aeovian Pharmaceuticals Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Aeovian Pharmaceuticals Inc. Private Company | 2012 | California, United States | < 10 | www.aeovian.com Private Company | 2012 | California, United States | < 10 | www.aeovian.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 1 Clinical Trials associated with Aeovian Pharmaceuticals Inc. ISRCTN62388748 / Completed Not Applicable A st … g Chairman and head of the Investment Committee at the Global Health Investment Fund, a groundbreaking impact-oriented venture fund in collaboration with the Gates Foundation, which successfully scaled both investment returns and health impact simultaneously. Dr. Greene earned his BA from Wesleyan University and his MD from UCSF. He was a Robert Wood Johnson Clinical Scholar at Yale and a Howard Hughes Medical Institute Research Scholar at the US National Institutes of Health … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
EP4532483A1 - Cd38-modulatoren und verwendungen davon - Google Patents EP4532483A1 - Cd38-modulatoren und verwendungen davon - Google Patents Cd38-modulatoren und verwendungen davon Info Publication number EP4532483A1 EP4532483A1 EP23735946.8A EP23735946A EP4532483A1 EP 4532483 A1 EP4532483 A1 EP 4532483A1 EP 23735946 A EP23735946 A EP 23735946A EP 4532483 A1 EP4532483 A1 EP 4532483A1 Authority EP European Patent Office Prior art keywords alkyl salt compound optionally substituted membered heterocycle Prior art date 2022-06-02 Legal status (The legal status is an assumption and is not a legal … s and makes no representation as to the accuracy of the status listed.) Pending Application number EP23735946.8A Other languages English ( en ) French ( fr ) Inventor John Kincaid Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Aeovian Pharmaceuticals Inc Original Assignee Aeovian Pharmaceuticals Inc Priority date (The priority date is an assumption and … sted.) 2022-06-02 Filing date 2023-06-02 Publication date 2025-04-09 2023-06-02 Application filed by Aeovian Pharmaceuticals Inc filed Critical Aeovian Pharmaceuticals Inc 2025-04-09 Publication of EP4532483A1 publication Critical patent/EP4532483A1/de Status Pending legal-status Critical Current Links Espacenet EPO GPI EP Register Global Dossier Discuss Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61P — SPECIFIC THERAP … f a compound or salt described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below. the therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one … an readily be determined by one of ordinary skill in the art. the term can also apply to a dose that can induce a particular response in target cells, e.g., reduction of proliferation or down regulation of activity of a target protein. the specific dose can vary depending on the particular compounds chosen, the dosing regimen to be followed, whet
EP4126229A4 - MTORC1 MODULATORS AND USES THEREOF - Google Patents EP4126229A4 - MTORC1 MODULATORS AND USES THEREOF - Google Patents MTORC1 MODULATORS AND USES THEREOF Download PDF Info Publication number EP4126229A4 EP4126229A4 EP21775952.1A EP21775952A EP4126229A4 EP 4126229 A4 EP4126229 A4 EP 4126229A4 EP 21775952 A EP21775952 A EP 21775952A EP 4126229 A4 EP4126229 A4 EP 4126229A4 Authority EP European Patent Office Prior art keywords mtorc1 modulators mtorc1 modulators Prior art date 2020-03-27 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not per … s and makes no representation as to the accuracy of the status listed.) Pending Application number EP21775952.1A Other languages German ( de ) English ( en ) French ( fr ) Other versions EP4126229A1 ( en Inventor John Kincaid Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Aeovian Pharmaceuticals Inc Original Assignee Aeovian Pharmaceuticals Inc Priorit … sted.) 2020-03-27 Filing date 2021-03-26 Publication date 2024-04-17 2021-03-26 Application filed by Aeovian Pharmaceuticals Inc filed Critical Aeovian Pharmaceuticals Inc 2023-02-08 Publication of EP4126229A1 publication Critical patent/EP4126229A1/en 2024-04-17 Publication of EP4126229A4 publication Critical patent/EP4126229A4/en Status Pending legal-status Critical Current Links Espacenet EPO GPI EP Register Global Dossier Discuss Classifications C — CHEMISTRY; METAL … AND USES THEREOF Pending EP4126229A4 ( en ) Applications Claiming Priority (8) Application Number Priority Date Filing Date Title US202063001177P 2020-03-27 2020-03-27 US202063001144P 2020-03-27 2020-03-27 US202063001187P 2020-03-27 2020-03-27 US202063019176P 2020-05-01 2020-05-01 US202063054768P 2020-07-21 2020-07-21 US202063054763P 2020-07-21 2020-07-21 US202063054762P 2020-07-21 2020-07-21 PCT/US2021/024536 WO2021195599A1 ( en ) 2020-03-27 2021-03-26 Mtorc1 modulators and … 4 true EP4126229A4 ( en ) 2024-04-17 Family ID=77892684 Family Applications (1) Application Number Title Priority Date Filing Date EP21775952.1A Pending EP4126229A4 ( en ) 2020-03-27 2021-03-26 MTORC1 MODULATORS AND USES THEREOF Country Status (11) Country Link US ( 3 ) US11634432B2 ( zh ) EP ( 1 ) EP4126229A4 ( zh ) JP ( 2 ) JP7606591B2 ( zh ) K
WO2022020522A3 - Mtorc1 modulators and uses thereof - Google Patents WO2022020522A3 - Mtorc1 modulators and uses thereof - Google Patents Mtorc1 modulators and uses thereof Download PDF Info Publication number WO2022020522A3 WO2022020522A3 PCT/US2021/042644 US2021042644W WO2022020522A3 WO 2022020522 A3 WO2022020522 A3 WO 2022020522A3 US 2021042644 W US2021042644 W US 2021042644W WO 2022020522 A3 WO2022020522 A3 WO 2022020522A3 Authority WO WIPO (PCT) Prior art keywords mtorc1 modulators mtorci diseases salts Prior art date 2020-07-21 Legal status (The legal status is an assumption and is not a … is and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/US2021/042644 Other languages French ( fr ) Other versions WO2022020522A2 ( en Inventor John Kincaid Alexandre Froidbise Guillaume EPPE Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Aeovian Pharmaceuticals Inc Original Assignee Aeovian Pharmaceutical … sted.) 2020-07-21 Filing date 2021-07-21 Publication date 2022-03-03 2021-07-21 Application filed by Aeovian Pharmaceuticals Inc filed Critical Aeovian Pharmaceuticals Inc 2021-07-21 Priority to EP21755213.2A priority Critical patent/EP4185590A2/en 2021-07-21 Priority to CN202511283802.2A priority patent/CN121426814A/en 2021-07-21 Priority to CN202180064530.0A priority patent/CN116322677B/en 2022-01-27 Publication of WO2022020522A2 publication Critical patent/WO2022020522A2/e … ulators and uses thereof Ceased WO2022020522A2 ( en ) Priority Applications (4) Application Number Priority Date Filing Date Title EP21755213.2A EP4185590A2 ( en ) 2020-07-21 2021-07-21 Mtorc1 modulators and uses thereof CN202511283802.2A CN121426814A ( en ) 2020-07-21 2021-07-21 MTORC1 regulator and its uses CN202180064530.0A CN116322677B ( en ) 2020-07-21 2021-07-21 MTORC1 regulators and uses thereof US18/157,224 US20230331737A1 ( en ) 2020-07-21 2023-01-20 Mtorc1 modulator … 023-01-20 Mtorc1 modulators and uses thereof Applications Claiming Priority (2) Application Number Priority Date Filing Date Title US202063054767P 2020-07-21 2020-07-21 US63/054,767 2020-07-21 Related Child Applications (1) Application Number Title Priority Date Filing Date US18/157,224 Continuation US20230331737A1 ( en ) 2020-07-21 2023-01-20 Mt
Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsy | Richard Gaster, M.D., Ph.D. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject … lled to welcome new investors Luma Group , Foresite Capital , CTI Life Sciences Fund , and Symbiosis who share the vision. Especially grateful for the TSC Alliance 's continued endorsement and investment through their Endowment Fund—a powerful validation of the program’s potential. Proud to have been part of Aeovian from the beginning, and hopeful for the meaningful impact it can bring to the TSC community. https://lnkd.in/gAr7H4aY Aeovian Pharmaceuticals Raises $55 Million t
John Kincaid Email Address & Phone Number | Chief Scientific Officer Of Aeovian Pharmaceuticals | Adapt.io Why Adapt? Platform Prospecting Adapt API Enrichment Useful Links Our Data Case Studies Data OS Solutions Personas Sales Marketing Use cases Email Finder Hyper-Personalization Lead Scoring & Routing Pricing Resources Blogs Build Your Marketing Stack Case Studies Partner Program About Us Sign In Request Demo Start Free Trial Why Adapt? Platform Prospecting Get access to fresh, accurate B2B data Adapt API Find leads directly from your browser Enrichment Empower your systems with Ada
John Kincaid - Chief Scientific Officer at Aeovian Pharmaceuticals | The Org Platform Enrich Pricing Log in Sign up Aeovian Pharmaceuticals John Kincaid Unverified JK John Kincaid Chief Scientific Officer Contact John Kincaid currently serves as the Chief Scientific Officer at Aeovian Pharmaceuticals since March 2020 and has been a Pharmaceutical Industry Consultant since January 2016. Prior experience includes roles as Scientific Co-Founder and Head of Discovery at NFlection Therapeutics from January 2017 to June 2019, as well as Vice President and Managing Director at Synterys, Inc. from D
--> John Kincaid | Aeovian top of page Home Science & Pipeline Team Patients News Contact JOHN KINCAID Chief Scientific Officer Mr. Kincaid joined Aeovian in March 2020 as Chief Scientific Officer. He brings 25 years of drug discovery experience where his teams have led several compounds into clinical trials. He is an Inventor on over 50 patent applications. Prior to joining, Mr. Kincaid was a scientific founder and acting Head of Discovery for Nflection Therapeutics, a company focused on novel therapies for patients with neurofibromatosis type 1. There he led a virtual discovery t
Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FD … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases October 3, 2019 | 4 min read Twitter LinkedIn Facebook Email Print venBio Partners and Sofinnova Investments co-lead Series A round alongside Apollo Health Ve … Aeovian’s differentiated and selective mTORC1 inhibitor approach can have broad application in rare diseases with high unmet need,” said Richard Gaster, a venBio Principal and Aeovian Director. “We look forward to initially pursuing rare CNS disease indications, but can see a large opportunity to also target age-related diseases more broadly.” “We are truly delighted to welcome these experienced life science venture firms to Aeovian,” said Jens Eckstein, Managing Partner at A … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING March 28, 2024 | 6 min read Twitter LinkedIn Facebook Email Print Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company dev … g Chairman and head of the Investment Committee at the Global Health Investment Fund, a groundbreaking impact-oriented venture fund in collaboration with the Gates Foundation, which successfully scaled both investment returns and health impact simultaneously. Dr. Greene earned his BA from Wesleyan University and his MD from UCSF. He was a Robert Wood Johnson Clinical Scholar at Yale and a Howard Hughes Medical Institute Research Scholar at the US National Institutes of Health … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Instagram Instagram Log In Sign Up Close Never miss a post from tscalliance Sign up for Instagram to stay in the loop. Sign up Log in tscalliance • Follow More options tscalliance 47w As a final wrap-up to the 2025 TSC International Research Conference: Engage, Accelerate, Transform, we would like to once again acknowledge the generous sponsors who made this conference possible and who continue to champion tuberous sclerosis complex (TSC) research, partnering with researchers to develop new treatments. Presenting Sponsor: Drs. Bonnie and Jonathan Rothberg & Family Featured Sponsor: Jazz Ph … Jazz Pharmaceuticals Poster Session Sponsors: Janice and Julian Gangoli Family Fund and @h_lundbeck Advocate Sponsors: The Gotschall Family; @neurelis ; Nobelpharma America, LLC; @praxismedicines ; @ucb_usa and Upsher-Smith Laboratories Welcome Reception Sponsors: TSC Alliance Board of Directors and TSC Alliance Endowment Fund Board of Directors Early Career Research Symposium Sponsor: Judy and Mark Schaengold Session Sponsors: Aeovian Pharmaceuticals; Biogen; Cassava Scienc
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manuf … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsy December 17, 2025 | 4 min read Twitter LinkedIn Facebook Email Print - Financing accelerates development of lead candidate AV078, a CNS-penetrant selective mTORC1 … t of lead candidate AV078, a CNS-penetrant selective mTORC1 inhibitor, and will fund completion of its Phase 2 clinical trial - Round co-led by Luma Group and CTI Life Sciences Fund, with participation from Foresite Capital, SymBiosis, the TSC Alliance Endowment Fund, Wilson Sonsini, and existing investors Apollo Health Ventures, Hevolution, Sofinnova Investments and venBio BERKELEY, Calif.--(BUSINESS WIRE)-- Aeovian Pharmaceuticals , a clinical-stage biopharmaceutical compan … ounced it has closed an oversubscribed $55 million Series B financing that will fund completion of a Phase 2 proof-of-concept study for its lead development candidate, AV078, in tuberous sclerosis complex (TSC)-related refractory epilepsy. The funding round was co-led by new investors Luma Group and CTI Life Sciences Fund, with participation from Foresite Capital, SymBiosis, the TSC Alliance Endowment Fund and Wilson Sonsini. Existing investors Apollo Health Ventures, Hevolut … tory. Through their investments in Series B funding, the TSC Alliance Endowment Fund, a supporting organization of the TSC Alliance, is also taking an active role in our mission to catalyze new treatments and drive research toward a cure for tuberous sclerosis complex.” Aeovian’s wholly-owned pipeline targets metabolic quality control by selectiv
Market Research Reports and Consulting – Global Insight Services Anti-Aging Drugs Market Size, Growth, Trends and Forecast | Global Insight Services US: +1-833-761-1700 [email protected] Submit Queries Home Reports Automotive & Transportation Chemicals & Materials Consumer Goods Energy & Natural Resources Food & Beverages Manufacturing & Construction Medical Devices Pharmaceuticals Semiconductors & Electronics Technology, Media, & Telecom Services Syndicated Reports Custom reports Consulting Services Subscriptions Insights Analyst Insights Press … able | End User: Hospitals & Clinics, Home Care, Wellness Centers, Others | Application: Skin Care, Hair Care, Bone & Joint Health, Immune Health, Age-related Disorders, Others | Gender: Female, Male | Published Date : April 2026 Report Code : GIS33621 Number of Pages : 350 Industry : Pharmaceuticals Reports Summary Table of Contents Companies Research Methodology Request Sample --> The global Anti Aging Drugs Market is projected to grow from $55.9 billion in 2025 to … l, Injectable End User Hospitals & Clinics, Home Care, Wellness Centers, Others Application Skin Care, Hair Care, Bone & Joint Health, Immune Health, Age-related Disorders, Others Gender Female, Male The expanding aging population is a major driver for the anti-aging drugs market, as rising life expectancy and a growing elderly demographic increase demand for preventive and therapeutic interventions. According to global estimates, the population aged 60 and above is expected … d Congress (AMWC) in Monaco. In December 2025, Oisín Biotechnologies received a grant from the Methuselah Foundation to advance its fat reduction study in pigs. In October 2025, Calico Life Sciences received fast track designation for an investigational therapy targeting Autosomal Dominant Polycystic Kidney Disease. In April 2025, Genflow partnered with Heureka Labs to develop AI-driven gene therapy solutions. In August 2024, Aeovian Pharmaceuticals highlighted emerging anti- … 102.4 Billion CAGR 0.064 SEGMENTS COVERED Type, Form, Stage, Product, End User, Application, Gender ANALYSIS COVERAGE Market Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events, SWOT Analysis and Developments Research Scope Estimates and forecasts the overall market size across type, applic
--> Team | Aeovian top of page Home Science & Pipeline Team Patients News Contact Executive Team Allison J. Hulme, PhD CEO & President John Kincaid Chief Scientific Officer Davis C. Ryman, MD, PhD Chief Medical Officer Micah Zajic Chief Financial Officer Board of Directors Allison J. Hulme, PhD CEO & President Richard Gaster, MD, PhD Director & Chairman Lars Ekman, MD, PhD Director Justin Gover Director William Greene, MD Director Nils Regge Director Themasap Khan, Ph.D. Director Youssef Bennani Director Scientific Advisors Dudley Lamming, PhD Scientific Advisor David Lowe, PhD
Aeovian Pharmaceuticals Inc. | Bona Investment & Management Co. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , P … eases, raised $55 million in Series B funding. Luma Group and CTI Life Sciences Fund led the round and were joined by Foresite Capital, SymBiosis, and others. https://lnkd.in/e8Eg6Tgw Aeovian Pharmaceuticals Inc. aeovian.com Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in More Relevant Posts Ahmed Gadelkareem 5mo Report this post Fortress Biotech (FBIO) is currently trading at $3.67, with a market cap of $113.91 million. The company focuses on ac … cent News and FDA Approval: - The FDA accepted the resubmission of the New Drug Application (NDA) for CUTX-101, aimed at treating Menkes disease, with a PDUFA target action date of January 14, 2026. - CUTX-101 previously received a Complete Response Letter (CRL) due to manufacturing issues, but the FDA classified the resubmission as Class 1, indicating minor issues. - Other pipeline assets include MB-106 for relapsed or refractory B-cell non-Hodgkin lymphomas and MB-107 for X
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING – venBio Skip to content Home Team Portfolio Firm Press Contact Investor login Home Team Portfolio Firm Press Contact Investor login Investor login BACK AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING March 28, 2024 First Cohort of Participants Dosed in Phase 1 Clinical Trial with Lead Development Candidate AV078 Intended for the Treatment of S
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Release … g Chairman and head of the Investment Committee at the Global Health Investment Fund, a groundbreaking impact-oriented venture fund in collaboration with the Gates Foundation, which successfully scaled both investment returns and health impact simultaneously. Dr. Greene earned his BA from Wesleyan University and his MD from UCSF. He was a Robert Wood Johnson Clinical Scholar at Yale and a Howard Hughes Medical Institute Research Scholar at the US National Institutes of Health … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
--> News | Aeovian top of page Home Science & Pipeline Team Patients News Contact Latest News & Events December 16, 2025 AEOVIAN PHARMACEUTICALS RAISES $55 MILLION TO ADVANCE FIRST-IN-CLASS SELECTIVE mTORC1 INHIBITOR FOR TUBEROUS SCLEROSIS COMPLEX-RELATED EPILEPSY March 28, 2024 AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING ©2026 by Aeovian Pharmaceuticals. All Rights Reserved. bottom of page
--> Aeovian Pharmaceuticals Inc. top of page Home Science & Pipeline Team Patients News Contact Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Read More Science & Pipeline Patients Team News & Events Our latest news and events Read More "We need a better response rate and less high-dose mediated side effects in the treatmen